TJ-CEO
2012 , Vol 7 , Num 1
Comparison of the Safety of Intracameral Cefuroxime and Moxifloxacin Injection for Prophylaxis of Endophthalmitis in Phacoemulsification Surgery
1M.D., Gölbaşı State Hospital Eye Clinic, Adıyaman/TURKEY2M.D. Associate Professor, Atatürk Training and Research Hospital 2nd Eye Clinic, Ankara/TURKEY
3M.D. Professor, Bozok University Faculty of Medicine, Department of Ophthalmology, Yozgat/TURKEY Purpose: The aim of this study was to evaluate and to compare the safety of intracameral cefuroxime and moxifloxacin injection at the end of cataract surgery for prophylaxis of endophthalmitis.
Materials and Methods: This prospective study is comprised of 60 eyes of 30 patients who had undergone bilateral but different day phacoemulsification surgery and another 30 patients who had unilateral phacoemulsification. The patients having bilateral surgery were randomly assigned to receive intracameral 1 mg/0.1 ml cefuroxime in one eye (Group 1), while in other eye, 250 μg/0.1 ml moxifloxacin was injected into the capsular bag at the end of surgery (Group 2). Patients who had unilateral phacoemulsification received intracameral BSS at the completion of the surgery (Group 3). Safety parameters, including visual acuity, intraocular pressure (IOP), corneal pachymetry, corneal clarity or edema, anterior chamber cells and flare and central foveal thickness measured by optical coherence tomography (OCT) were evaluated preoperatively and on the 1st, 7th, 30th and 90th days postoperatively. Corneal endothelial cell counts were assessed preoperatively and on the 30th and 90th days postoperatively.
Results: There were no statistically significant difference between the groups in age, cataract hardness, phaco time, total operation time, fluid used( p>0.05). There were no significant difference between the groups in visual acuity, IOP, corneal edema, anterior chamber reaction, OCT results and endothelial cell counts.
Conclusion: There was no anterior and posterior segment toxicity risk with intracameral injection of 1 mg/0.1 ml cefuroxime and 250 μg/0.1 ml moxifloxacin for prophylaxis of endophthalmitis after cataract surgery, and their intracameral injection were found to be as safe as BSS. Keywords : Prophylaxis of endophthalmitis, moxifloxacin, cefuroxime